EGFR and breast carcinoma: This study led to the identification of important phosphoproteins including many known Her2 and EGFR signaling proteins, as well as previously unidentified Her2 signaling proteins, such as Stat1, Dok1, and δ-catenin, providing valuable leads for designing optimal future therapies in Her2-related breast cancer.